Risk-Benefit of Geographic Atrophy Treatment
David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.
Patient Characteristics in Geographic Atrophy
David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.
Role of the Complement System in Geographic Atrophy
David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.
Biomarkers in Geographic Atrophy
David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.
Understanding Geographic Atrophy
David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.
Advice to Physicians Treating Geographic Atrophy
Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.
Bringing Ocular Imaging to Primary Care Practices
Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.
Improving Referral for Geographic Atrophy
Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.
Introduction of New Geographic Atrophy Treatments in Practice
A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.
Ensuring Adherence to Geographic Atrophy Treatment
Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.
Guidance for Treatment Selection in Geographic Atrophy
An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.
Other Complement Inhibitors for Geographic Atrophy Treatment
Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.
Pegcetacoplan and Monitoring in Geographic Atrophy
A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.
Treatment of Both Eyes and Subfoveal Lesions in Geographic Atrophy
Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.
Frequency of Pegcetacoplan Administration for Geographic Atrophy Treatment
Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.
Pegcetacoplan for Treatment of Geographic Atrophy
A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.
Pathophysiology, Treatment Targets and Options in Geographic Atrophy
An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.
Geographic Atrophy Management in Clinical Practice
Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.
Imaging Modalities in Geographic Atrophy
David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.
Progression of Geographic Atrophy Over Time
Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.
Discussing Management of Age-Related Macular Degeneration (AMD) with the Patient
A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.
Impact of Geographic Atrophy on the Caregiver
Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.
Disease Burden and Tools to Manage Geographic Atrophy
An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.
Patient Communication Regarding Visual Function in Geographic Atrophy
Jayanth Sridhar, MD, Nancy M. Holekamp, MD, FASRS, and David R. Lally, MD, share their thoughts on measuring visual changes to determine how their patients’ geographic atrophy is progressing.
Overview of Geographic Atrophy (GA)
Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp provide an overview of age-related macular degeneration and risk of developing geographic atrophy (GA).
Practical Takeaways and Future Directions in DME and AMD
Retina specialists share advice and practice pearls regarding the management of DME and neovascular AMD, including counseling patients about the importance of healthy lifestyles.
What’s on the Horizon for DME and AMD
Carl D. Regillo, MD, FACS, leads a discussion with retina specialists about the future of care for AMD and DME, including tyrosine kinase inhibition and gene therapy.
Practical and Clinical Implications for a Rapidly Changing Treatment Landscape in DME and AMD
Retina specialists discuss concerns and apprehensions that both physicians and patients may feel towards newer modalities and delivery mechanisms for the treatment of AMD and DME.
Reviewing Investigational Agents for the Treatment of DME and AMD
Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, talk about important data that has awaited for several newer and investigational therapies for DME and AMD.
Biosimilars for DME and AMD
Carl D. Regillo, MD, FACS, and Michael A. Klufas, MD, discuss the possible impact of biosimilars and share important considerations regarding cost and safety.
2 Clarke Drive Cranbury, NJ 08512